Results 11 to 20 of about 13,925,210 (307)

Second-line treatment options in hepatocellular carcinoma [PDF]

Drugs in Context, 2019
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed ...
Donatella Marino, Clizia Zichi, Marco Audisio, Elisa Sperti, Massimo Di Maio   +4 more
doaj   +2 more sources

Association of First-Line and Second-Line Antiretroviral Therapy Adherence [PDF]

Open Forum Infectious Diseases, 2014
Background.  Adherence to first-line antiretroviral therapy (ART) may be an important indicator of adherence to second-line ART. Evaluating this relationship may be critical to identify patients at high risk for second-line failure, thereby exhausting their treatment options, and to intervene and improve patient outcomes.Methods.
Ramadhani, Habib O., Bartlett, John A., Thielman, Nathan M., Pence, Brian W., Kimani, Stephen M., Maro, Venance P., Mwako, Mtumwa S., Masaki, Lazaro J., Mmbando, Calvin E., Minja, Mary G., Lirhunde, Eileen S., Miller, William C.   +11 more
openaire   +4 more sources

Second-Line Treatment for Pancreatic Cancer [PDF]

JOP : Journal of the pancreas, 2014
Although standard of care for treatment of pancreatic cancer is established in the first line setting, there is limited data to support standard for second line chemotherapy for advanced pancreatic cancer. This is starting to change, as new studies have shown positive effect on overall survival in the second line setting.
Nancy, Kaddis, Muhammad Wasif, Saif
openaire   +3 more sources

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

Cancer Medicine, 2020
Background Patients with advanced hepatocellular carcinoma (HCC) who received second line sorafenib plus doxorubicin following disease progression on sorafenib were shown retrospectively to have improved progression free survival (PFS) and overall ...
Imane El Dika, Marinela Capanu, Joanne F. Chou, James J. Harding, Michele Ly, Anna D. Hrabovsky, Richard K.G. Do, Jinru Shia, Brittanie Millang, Jennifer Ma, Eileen M. O’Reilly, Ghassan K. Abou‐Alfa   +11 more
doaj   +1 more source

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience

Current Oncology, 2023
Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase ...
Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu   +13 more
doaj   +1 more source

Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data. [PDF]

, 2015
OBJECTIVES: Rates of first-line treatment failure and switches to second-line therapy are key indicators for national HIV programmes. We assessed immunological treatment failure defined by WHO criteria in the Tanzanian national HIV programme. METHODS: We
Ramadhani, Angela, Vanobberghen, Fiona M, Mmbando, Donan, Wringe, Alison, Todd, Jim, Zaba, Basia, Kilama, Bonita   +6 more
core   +1 more source

Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. [PDF]

, 2012
Article approval pendingTenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of ...
Brennan, Alana, Olivia Keiser, Cleophas Chimbetete, Lloyd Mulenga, Giddy, Janet, Egger, Matthias, Hans Prozesky, Janet Giddy, Wandeler, Gilles, Alana Brennan, Christopher J. Hoffmann, Robin Wood, Thom Chaweza, Chaweza, Thom, Daniela Garone, Gilles Wandeler, Matthias Egger, Keiser, Olivia, Mulenga, Lloyd, Hoffmann, Christopher J, Chimbetete, Cleophas, Prozesky, Hans, Boulle, Andrew, Garone, Daniela, IeDEA Southern Africa Collaboration,, Andrew Boulle, Wood, Robin, Egger M, Wandeler G, Giddy J, Hoffmann CJ, Chimbetete C, Garone D, Chaweza T, Mulenga L, Boulle A, Brennan A, Prozesky H, Wood R, Keiser O   +39 more
core   +3 more sources

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization

Current Oncology, 2022
Background: In the ATLANTIS study, second-line lurbinectedin/doxorubicin did not improve overall survival (OS), however patients with a chemotherapy-free interval (CTFI) of ≥180 days had an improved progression free survival (PFS).
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho   +3 more
doaj   +1 more source

Targeted drugs in the second line anticancer therapy of disseminated colorectal cancer

Медицинский совет, 2015
For many years, colorectal cancer has been one of the most common tumor diseases in the world. However, treatment outcomes for patients with metastatic colorectal cancer have long remained quite poor. The development of targeted therapy had a significant
K. A. Vorontsova, E. V. Chernoglazova, G. V. Vyshinskaya   +2 more
doaj   +1 more source

Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use

Медицинский совет, 2022
Urothelial cancer occupies a significant place in the routine practice of cancer treatment. Systemic antitumor treatment of patients with metastatic urothelial cancer in the first line is currently well studied, has its own standards, implemented in ...
A. A. Gritskevich, A. Yu. Popov, I. G. Rusakov, E. K. Vozniy, V. A. Makarov, D. I. Gridnev, T. P. Baitman, S. V. Mishugin, I. V. Novikova, S. V. Khromova   +9 more
doaj   +1 more source